A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …

Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function …

Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …

Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological
processes, indicating the potential for common approaches to treatment. Nintedanib …

Objectives One of the most significant features of poor prognosis in COVID-19 is pulmonary
fibrosis. Nintedanib is a new antifibrotic agent that interferes with processes of pulmonary …

Rheumatoid arthritis (RA) is a type of inflammatory arthritis that affects~ 1% of the general
population. Although arthritis is the cardinal symptom, many extra-articular manifestations …

Objectives To examine the effectiveness of Janus-kinase inhibitors (JAKis) or abatacept
(ABA) in patients with rheumatoid arthritis-interstitial lung disease (RA-ILD). Methods …

The aim of this study was to compare radiology-based prediction models in rheumatoid
arthritis-related interstitial lung disease (RAILD) to identify patients with a progressive …

Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of
idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of …